EGFR and non-small cell lung carcinoma: Additionally, the early adaptive process of acquired resistance of the EGFR-mutant NSCLC to tyrosine-kinase-inhibitors (TKI), was linked to increased mitochondrial mass and performance of OXPHOS [193].